Biosimilars in Finland

The following biomisimilars were available in the Finnish markets on 1.2.2018:

Name Active substance Reference product
Insulin lispro Sanofi insulin lispro Humalog
Ritemvia rituximab MabThera
Binocrit epoetin alfa Eprex/Erypo
Retacrit epoetin zeta Eprex/Erypo
Accofil filgrastim Neupogen
Nivestim filgrastim Neupogen
Ratiograstim filgrastim Neupogen
Zarzio filgrastim Neupogen
Bemfola follitropin alfa GONAL-f
Inflectra infliximab Remicade
Remsima infliximab Remicade
Abasaglar insulin glargine Lantus
Omnitrope somatropin Genotropin
Erelzi etanercept Enbrel